Behold.ai

What was red dot?

Red dot triaged chest X-rays and raised a red-dot alert on flagged images. It ruled out normal scans and prioritized suspected lung cancer and pneumothorax. The FDA granted a 510(k) under K191556 for Red Dot, filed by Behold.Ai Technologies Limited, with a decision date of February 28, 2020 (product code QFM). Radiology Business reported the clearance for pneumothorax triage in March 2020. It is the only Behold.ai entry in the FDA's 510(k) database.

What happened to the company?

An earlier Behold.ai was founded in New York in 2015, and Simon Rasalingham acquired it in March 2018. Behold.ai Technologies Limited was incorporated in the UK in August 2017, per Tracxn. The Digital Health News headline reports the January 2025 administration, and its summary ties it to the company winning no contracts under the UK government's AI Diagnostic Fund. Founder Simon Rasalingham called for an inquiry into the £21 million fund after the company failed to win contracts, in the same outlet's reporting.

Dealroom lists a £1.5 million seed round in July 2018 and a £2.1 million round in January 2021. LeadIQ puts total funding at $2.9 million over five rounds, and Tracxn puts it at $100,000.

Did red dot survive?

Dealroom reports that a new company, Behold.ai Global Technologies Limited, bought the intellectual property and assets of Behold.ai with a plan to relaunch red dot. No transfer of K191556 to a new owner has been reported.

What did red dot cost?

No public price is documented for red dot, and the vendor's website is offline.

The verdict

Red dot is discontinued as of January 2025. Dealroom reports a relaunch by a successor company, and the FDA clearance of February 2020 remains in the 510(k) database under Behold.Ai Technologies Limited.